Emerging drugs for endometriosis
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Medical treatment of endometriosis relies on drugs that suppress ovarian steroids and induce an hypoestrogenic state that causes atrophy of ectopic endometrium. Gonadotrophin-releasing hormone (GnRH) analogues, danazol, progestogens and oestrogen-progestin combinations have all proven effective in relieving pain and reducing the extent of endometriotic implants. However, symptoms often recur after discontinuation of therapy and hypoestrogenism-related side effects limit the long-term use of most medications. Furthermore, these therapies are of limited value in patients with a desire to become pregnant because they inhibit ovulation. An important target for current research is to identify effective therapies that can be safely administered in the long term. GnRH analogues with add-back therapy, progestogens and continuous oral contraceptive are options available for a medium or long-term systemic treatment. Mifepristone, an antiprogestogen, may constitute an alternative if encouraging preliminary data on its effectiveness and tolerability are confirmed. A very appealing area of interest is the possibility of treating endometriosis without suppressing ovarian function. Aromatase inhibitors might have such characteristics as they have been shown to inhibit oestrogen production selectively in endometriotic lesions, without affecting ovarian function; the clinical role of these drugs in the treatment of endometriosis is under evaluation. Levonorgestrel medicated intrauterine device has proven effective in relieving dysmenorrhoea associated with endometriosis, as well as pain associated with rectovaginal endometriosis. Although a systemic absorption is present determining side effects, this approach is promising in the long-term management of this condition. A fundamental objective of research in endometriosis treatment is to develop new therapeutic approaches based on the findings from experimental studies on the aetiopathogenesis of the disease; current research is focusing on anti-inflammatory drugs and modulators of the immune system. TNF-binding protein-1 and IL-12 have proved effective in reducing endometriotic lesions in animal models, while pentoxifylline and INF-alpha 2b have shown encouraging results in clinical studies. This area may be of paramount importance in the near future in order to develop a therapy that could prevent or eradicate endometriosis rather than merely relieving the symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nisolle, M., & Donnez, J. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)00191-x · Cited by 1,279
Mitwally, M. F. M., & Casper, R. F. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01705-2 · Cited by 800 · cited 1×
“5 mg letrozole in days 3 – 7 of the menstrual cycle is able to induce ovulation in anovulatory patients [67].”
BackgroundThe Epidemiology of Endometriosis
CRAMER, D. W., & MISSMER, S. A. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb02761.x · Cited by 539
The Relation of Endometriosis to Menstrual Characteristics, Smoking, and Exercise
Cramer, D. W. (1986) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1986.03370140102032 · Cited by 367
Vercellini, P., Trespidi, L., Colombo, A., Vendola, N., Marchini, M., & Crosignani, P. G. (1993) · Fertility and Sterility · doi:10.1016/s0015-0282(16)56039-7 · Cited by 311 · cited 1×
“In a previous paper, a lowdose cyclic OC (n = 28) was compared with goserelin depot (n = 29) in women with pelvic pain associated with endometriosis [60].”
Kitawaki, J., Noguchi, T., Amatsu, T., Maeda, K., Tsukamoto, K., Yamamoto, T., Fushiki, S., Osawa, Y., & Honjo, H. (1997) · Biology of Reproduction · doi:10.1095/biolreprod57.3.514 · Cited by 305
Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis
Fedele, L., Bianchi, S., Zanconato, G., Portuese, A., & Raffaelli, R. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01759-3 · Cited by 290 · cited 2×
“In fact, irregular periods, breast tenderness, mood changes, acne, seborrhoea, weight gain, abdominal bloating and headache were observed during treatment [71,72].”
BackgroundMethodSelf-citationVercellini, P., Frontino, G., De Giorgi, O., Pietropaolo, G., Pasin, R., & Crosignani, P. G. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00794-5 · Cited by 289 · cited 1×
“[61] have treated, with continuous OC for 2 years, 50 patients who had experienced recurrent dysmenorrhoea during cyclic assumption of OC after conservative surgery for endometriosis.”
BackgroundDlugi, A. M., Miller, J. D., & Knittle, J. (1990) · Fertility and Sterility · doi:10.1016/s0015-0282(16)53755-8 · Cited by 279
Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target
Zeitoun, K. M., & Bulun, S. E. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00393-3 · Cited by 256 · cited 2×
“[62] reported a case of symptomatic recurrent endometriosis in an overweight postmenopausal patient who had already undergone transabdominal hysterectomy and bilateral salpingo-oophorectomy, in whom the endometriotic vaginal lesion disappeared after 9 months of treatment with anastrozole 1 mg/day.”
Background
Cited by
Petta, C. A., Ferriani, R. A., Abrao, M. S., Hassan, D., Rosa e Silva, J. C., Podgaec, S., & Bahamondes, L. (2005) · Human Reproduction · doi:10.1093/humrep/deh869 · Cited by 363
“Waiting for Godot”: a commonsense approach to the medical treatment of endometriosis
Vercellini, P., Crosignani, P., Somigliana, E., Vigano, P., Frattaruolo, M. P., & Fedele, L. (2011) · Human Reproduction · doi:10.1093/humrep/deq302 · Cited by 180
“In the past few years, many experts published reviews on forthcoming medications for the disease (D’Hooghe, 2003; Nothnick and D’Hooghe, 2003; Fedele and Berlanda, 2004; Olive et al., 2004; Attar and Bulun, 2006; Chlouber et al., 2006; Crosignani et al., 2006a; Mihalyi et al., 2006; Hompes and…”
BackgroundInfluentialSelf-citationUreteral and Vesical Endometriosis: Two Different Clinical Entities Sharing the Same Pathogenesis
Berlanda, N., Vercellini, P., Carmignani, L., Aimi, G., Amicarelli, F., & Fedele, L. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e3181c4bc3a · Cited by 119
Self-citationTwo unsuccessful clinical trials on endometriosis and a few lessons learned
Guo, S.-W., & Olive, D. L. (2007) · Gynecologic and Obstetric Investigation · doi:10.1159/000098413 · Cited by 49
Mei, L., Bao, J., Tang, L., Zhang, C., Wang, H., Sun, L., Ma, G., Huang, L., Yang, J., Zhang, L., et al. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.01.012 · Cited by 36
Metadata
- Authors
- Fedele, L., & Berlanda, N.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa Healthcare
- Published
- 2004-05
- Volume
- 9
- Issue
- 1
- Pages
- 167-177
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2051572011
- Cited by
- 73
- References
- 21
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging drugs for endometriosis. https://app.cochat.ai/papers/10.1517/14728214.9.1.167
- The paper
- Fedele, L., & Berlanda, N. (2004). Emerging drugs for endometriosis. Expert Opinion on Emerging Drugs. https://doi.org/10.1517/14728214.9.1.167
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.